| Ulcerative Colitis |
1 |
1 |
| Thromboembolism |
0 |
0.66 |
| Food and Drug Administration (FDA) |
0 |
0.98 |
| HIV Infection |
0 |
0.57 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.55 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.54 |
| Cardiovascular Risk Management |
0 |
0.52 |
| Juvenile Rheumatoid Arthritis (JRA) |
0 |
0.44 |
| Arthritis |
0 |
0.99 |
| Rheumatoid Arthritis |
0 |
0.42 |
| Psoriatic Arthritis |
0 |
0.34 |
| Thrombus |
0 |
0.26 |
| Blood |
0 |
0.18 |
| Colitis |
0 |
0.18 |
| Inflammatory Bowel Disease |
0 |
0.18 |
| Lung Cancer |
0 |
0.16 |
| Cancer |
0 |
0.12 |
| Cerebrovascular Accident |
0 |
0.1 |
| California |
0 |
0.06 |
| Drug and Treatment Safety |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Lung |
0 |
0.06 |
| Lymphoma |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Thrombosis |
0 |
0.06 |
| Tumor |
0 |
0.06 |
| Washington |
0 |
0.06 |